The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

PDE Inhibitors Market, 2016-2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    October 2016

  • Pages
    233

  • View Count
    1222

Example Insights

  1. Around 40 PDE inhibitors are currently in various stages of clinical / preclinical development. PDE4 and PDE5 inhibitors, each occupying over 30% share of the pipeline, have emerged as the most prominent PDE inhibitor subtypes.
  2. Several molecules are under development for the treatment of neurological diseases (36%), such as schizophrenia, Alzheimer’s disease and Huntington’s disease; most of these molecules are in early development phases. Other key therapeutic areas include genitourinary diseases (25%) and cardiovascular diseases (11%).
  3. Although the market was initially led by large-size pharma players (such as AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer), the current market is characterized by the presence of several small / mid-sized pharma players. Notable examples of small firms and start-ups include (in alphabetical order) BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritechbiopharm, VIVUS, Verona Pharma, and vtv Therapeutics.
  4. Several research institutes, companies and organizations have made significant contribution to the overall development of these therapeutics. During our research, we identified over 400 key opinion leaders who have played critical role in the development of PDE inhibitors. Lee Zane (Anacor Pharmaceuticals / Pfizer), Sae Woong Kim (Catholic University Medical College), Dave Singh (Medicines Evaluation Unit) and Min-Gul Kim (Chonbuk National University Hospital) are some of the well-known researchers who have done exemplary work in this field.
  5. With the presence of already approved PDE inhibitors such as Viagra® and Cialis®, trends on social media platform have indicated growing trend. In fact, we were able to capture around 2.7 million tweets of relevant keywords over last five years on Twitter.
  6. It is important to highlight that the impending patent expiries of currently approved drugs is expected to negatively impact the market’s growth in the short-term. However, it is poised to gain momentum post 2021 after the anticipated approval of a number of late stage product candidates. By 2026, we expect that the overall PDE inhibitors market could be worth over USD 10 billion.

Overview

The discovery of the second messengers, cAMP and cGMP, in 1958 led to a deeper understanding of the signal transduction processes behind physiological stimulation and response. Later, the identification of phosphodiesterases (PDEs) and the establishment of their role in diseases led to the development of drugs targeting this class of enzymes. PDEs are a complex superfamily of metallophosphohydrolase enzymes that regulate the activity of second messengers. The superfamily consists of 11 different gene families, ranging from PDE1 to PDE11. These enzymes can be differentiated, in terms of their 3D-structure, modes of regulation, cellular localization and sensitivity to inhibitors.

Until 1998, only non-selective PDE inhibitors were available in the market and were primarily indicated for providing symptomatic relief for respiratory diseases, including COPD and asthma. Post the launch of Viagra in 1998, several selective PDE inhibitors came into the market. At present, there are 13 PDE inhibitors commercially available in different geographies. Due to the involvement of PDEs in multiple cellular processes, inhibitors against these molecular targets are applicable across a diverse range of disease indications. It is worth mentioning that the introduction of PDE inhibitors brought a radical change in the treatment of erectile dysfunction. Consequently, these molecules now occupy a major share in the erectile dysfunction market. In addition, PDE inhibitors are also being developed to address the current unmet need for pharmacological interventions for the treatment of patients suffering from certain neurological diseases, cardiovascular diseases, respiratory diseases and dermatological diseases. Drug candidates targeting schizophrenia, atopic dermatitis, Huntington’s disease, COPD, asthma and Alzheimer’s disease are all in various phases of clinical development.

The success of the marketed PDE inhibitors has prompted several industry players to undertake initiatives in this area. The fragmented nature of the market is expected to increase the pace of innovation; as more molecules advance to late stage development and eventually get commercialized, we expect the new entrants to actively monetize this growing opportunity.

 

Scope of the Report

The "PDE Inhibitors Market, 2016-2026" study offers a comprehensive analysis of the current landscape of these therapies and an informed opinion on how the field is likely to evolve over the next decade. The market has gained traction during the last few years with many drug candidates designed to address a wide range of diseases. PDE5, with two blockbuster drugs (Viagra® and Cialis®), is one of the most researched PDE inhibitor subtype. In the recent past, another PDE inhibitor subtype, PDE4, has surfaced to address the unmet needs associated with respiratory diseases and dermatological disorders.

Among other things, the report provides the following information:

  • A detailed overview of the PDE inhibitors pipeline covering marketed, clinical and preclinical therapies. We have presented information on the respective phases of development, key players involved, PDE inhibitor subtypes, routes of administration and indications being targeted by specific drug candidates.
  • Comprehensive profiles highlighting clinical trial details, key clinical results and future market opportunity for the marketed and late stage (phase II and phase III) PDE inhibitors.
  • A list of key opinion leaders (KOLs) who have been involved in the discovery and development of PDE inhibitors.
  • A discussion on emerging trends and the popularity of PDE inhibitors as observed on social media platforms, such as Twitter, over the last few years.
  • A discussion on the potential side effects and the warnings issued by regulatory authorities, indicating areas of improvement for future drug development.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters such as target consumer segments, likely adoption rates and expected pricing, we have provided an estimate of the size of the market in the short-mid-term and long term. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions with experts in the industry. All figures and technical details presented in the report have been sourced and analyzed from publicly available data. All financial figures mentioned in this report are in USD, unless specified otherwise.

Contents

Chapter 2  provides an executive summary of the report. It offers a high level view on the evolution of PDE inhibitors market in the mid to long term.        

Chapter 3  provides an introduction to PDE enzyme superfamily, including details on the historical timeline of this class of therapeutics and information on different PDE isozymes. The chapter highlights the structure of these enzymes and their role in different cellular activities. It also contains comprehensive information about selective and non-selective PDE inhibitors. In addition, the chapter provides details on the design of PDE inhibitors as well as importance of substrate specificity and potency.

Chapter 4  includes information on over 50 molecules that are either approved or are being evaluated in different stages of development (clinical / preclinical). It features a detailed and comprehensive analysis of the pipeline molecules highlighting the key therapeutic indications, PDE subtypes, phases of development, routes of administration and leading players in the field of PDE inhibitors.

Chapter 5  contains information on various genitourinary and cardiovascular diseases targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of genitourinary and cardiovascular diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results. In addition, the chapter highlights the emerging trends on social media related to PDE inhibitors. It presents an overview of the popularity of the keywords  phosphodiesterase inhibitor  and  PDE inhibitor  on Twitter over the last five years.

Chapter 6  contains information on various neurological diseases being targeted by different PDE inhibitors. In addition to other elements, we have provided details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides comprehensive profiles of drug candidates in development (phase II or higher) for the treatment of neurological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results. 

Chapter 7  contains information on various dermatological diseases being targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication. The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of dermatological diseases. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.

Chapter 8  contains information on various respiratory diseases and other key indications targeted by different PDE inhibitors. In addition to other elements, we have covered details on disease epidemiology and information on specific PDE inhibitors that are involved in the treatment of a particular indication.  The chapter also provides detailed profiles of the molecules in development (phase II or higher) for the treatment of respiratory diseases and other key indications. Each profile presents an overview of the drug developer, portfolio of PDE inhibitors, details on clinical trials, current status of development and key clinical results.

Chapter 9  presents an analysis of the key opinion leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies and the highest phase of development of a clinical trial investigated by them.

Chapter 10  presents a detailed market forecast of PDE inhibitors and a discussion on the overall financial opportunity in this domain. It includes future sales projections for 13 molecules in advanced stages of development. These estimates take into account the target patient population, the existing competition, likely adoption rate and the expected price of each therapy.

Chapter 11  focusses on the various side effects reported by patients treated using these drugs. In addition, the chapter lists the PDE inhibitors that have been terminated during development due to various reasons.

Chapter 12  provides a summary of the overall report. In this chapter, we present a list of key takeaways from the report and our independent opinion on the nature and potential of the PDE inhibitors market. The insights presented in this chapter are based on the research and analysis described in previous chapters.

Chapter 13  contains a collection of interview transcripts of discussions held with some of the key players in the industry.

Chapters 14 and 15  are appendices, which provide tabulated data and a list of companies mentioned in the report, respectively.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Phosphodiesterases: A Brief History
3.3. Phosphodiesterases: An Overview
3.3.1. PDE Isozymes: Structure
3.3.2. PDE Isozymes: Function
3.4. PDE Inhibitors
3.4.1. Designing PDE Inhibitors
3.4.2. Substrate Specificity and Potency
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. PDE Inhibitors: A Promising Pipeline
4.3. PDE Inhibitors: Pipeline Analysis
4.3.1. PDE Inhibitors: Distribution by Phase of Development
4.3.2. PDE Inhibitors: Distribution by PDE Subtypes
4.3.3. PDE Inhibitors: Distribution by Therapeutic Areas
4.3.4. PDE Inhibitors: Distribution by Route of Administration
4.3.5. PDE Inhibitors: Distribution by Geography
4.3.6. PDE Inhibitors: Leading Players
 
5. GENITOURINARY AND CARDIOVASCULAR DISEASES
5.1. Context and Background
5.2. Genitourinary Diseases
5.2.1. Erectile Dysfunction
5.2.1.1. Introduction and Epidemiology
5.2.1.2. Most Prominent PDE Inhibitor Subtypes
 
5.3.1. Pulmonary Hypertension
5.3.1.1. Introduction and Epidemiology
5.3.1.2. Most Prominent PDE Inhibitor Subtypes
 
5.4. PDE Inhibitors under Development for Genitourinary Diseases and Cardiovascular Diseases
5.5. Hanmi Pharmaceutical
5.5.1. Company Overview
5.5.2. Financial Performance
5.5.3. PDE Inhibitor Pipeline
5.5.3.1. HGP1207
5.5.3.1.1. Product Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Trials
5.5.3.2. HCP1303
5.5.3.2.1. Product Overview
5.5.3.2.2. Current Status of Development
5.5.3.2.3. Clinical Trials
 
5.6. PDE Inhibitors: Trends on Social Media
5.7. Trend on Twitter
5.7.1. Most Popular Marketed Drugs
5.7.2. Most Popular PDE Inhibitor Subtypes
5.7.2.1. Most Popular Keywords (Word Cloud Representation)
 
6. NEUROLOGICAL DISEASES
6.1. Chapter Overview
6.2. Schizophrenia
6.2.1. Introduction and Epidemiology
 
6.3. Huntington’s Disease
6.3.1. Introduction and Epidemiology
6.3.2. Most Prominent PDE Inhibitor Subtypes
 
6.4. Alzheimer’s Disease
6.4.1. Introduction and Epidemiology
6.4.2. Most Prominent PDE Inhibitor Subtypes
 
6.5. PDE Inhibitors under Development for Neurological Diseases
6.6. Boehringer Ingelheim
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. PDE Inhibitor Pipeline
6.6.3.1. BI 409306
6.6.3.1.1. Product Overview
6.6.3.1.2. Current Status of Development
6.6.3.1.3. Clinical Trials
6.6.3.1.4. Key Clinical Trial Results
 
6.7. Takeda Pharmaceuticals
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. PDE Inhibitor Pipeline
6.7.3.1. TAK-063
6.7.3.1.1. Product Overview
6.7.3.1.2. Current Status of Development
6.7.3.1.3. Clinical Trials
6.7.3.1.4. Key Clinical Trial Results
 
6.8. Pfizer
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. PDE Inhibitor Pipeline
6.8.3.1. PF-02545920
6.8.3.1.1. Product Overview
6.8.3.1.2. Current Status of Development
6.8.3.1.3. Clinical Trials
6.8.3.1.4. Key clinical Trial Results
6.8.4. Collaborations
 
6.9. Dart NeuroScience
6.9.1. Company Overview
6.9.2. PDE Inhibitor Pipeline
6.9.2.1. HT-0712 / IPL-455903
6.9.2.1.1. Product Overview
6.9.2.1.2. Current Status of Development
6.9.2.1.3. Clinical Trials
6.9.2.1.4. Key Clinical Trial Results
 
6.10. Omeros Corporation
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. PDE Inhibitor Pipeline
6.10.3.1. OMS824
6.10.3.1.1. Product Overview
6.10.3.1.2. Current Status of Development
6.10.3.1.3. Clinical Trials
6.10.3.1.4. Key Clinical Trial Results
6.10.4. Collaborations
 
7. DERMATOLOGICAL DISORDERS
7.1. Chapter Overview
7.2. Atopic Dermatitis
7.2.1. Introduction and Epidemiology
7.2.2. Most Prominent PDE Inhibitor Subtypes
 
7.3. Psoriasis
7.3.1. Introduction and Epidemiology
7.3.2. Most Prominent PDE Inhibitor Subtypes
 
7.4. PDE Inhibitors under Development For Dermatology
7.5. Anacor Pharmaceuticals (a part of Pfizer)
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. PDE Inhibitor Pipeline
7.5.3.1. Crisaborole / AN2728
7.5.3.1.1. Product Overview
7.5.3.1.2. Current Status of Development
7.5.3.1.3. Clinical Trials
7.5.3.1.4. Key Clinical Trials
 
7.6. Otsuka
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. PDE Inhibitor Pipeline
7.6.3.1. OPA-15406 / MM36
7.6.3.1.1. Product Overview
7.6.3.1.2. Current Status of Development
7.6.3.1.3. Clinical Trials
7.6.3.1.4. Key Clinical Trial Results
7.6.4. Collaborations
 
7.7. Roivant Sciences
7.7.1. Company Overview
7.7.2. PDE Inhibitor Pipeline
7.7.2.1. RVT-501
7.7.2.1.1. Product Overview
7.7.2.1.2. Current Status of Development
7.7.2.1.3. Clinical Trials
7.7.2.1.4. Key Clinical Trial Results
7.7.3. Collaborations
 
8. RESPIRATORY DISEASES AND OTHER INDICATIONS
8.1. Chapter Overview
8.2. Respiratory Diseases
8.2.1. COPD
8.2.1.1. Introduction and Epidemiology
8.2.1.2. Most Prominent PDE Inhibitor Subtypes
 
8.2.2. Asthma
8.2.2.1. Introduction and Epidemiology
8.2.2.2. Most Prominent PDE Inhibitor Subtypes
8.2.3. PDE Inhibitors under Development for Respiratory Diseases
 
8.3. Other Indications
8.3.1. NAFLD / NASH
8.3.1.1. Introduction and Epidemiology
8.3.1.2. Most Prominent PDE Inhibitor Subtypes
8.3.2. PDE Inhibitors under Development for Other Indications
 
8.4. Chiesi Farmaceutici
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. PDE Inhibitor Pipeline
8.4.3.1. CHF6001
8.4.3.1.1. Product Overview
8.4.3.1.2. Current Status of Development
8.4.3.1.3. Clinical Trials
8.4.3.1.4. Key Clinical Trial Results
 
8.5. Verona Pharma
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. PDE Inhibitor Pipeline
8.5.3.1. RPL554
8.5.3.1.1. Product Overview
8.5.3.1.2. Current Status of Development
8.5.3.1.3. Clinical Trials
8.5.3.1.4. Key Clinical Trial Results
8.5.4. Collaborations
 
8.6. NuSirt Biopharma
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. PDE Inhibitor Pipeline
8.6.3.1. NS-0200
8.6.3.1.1. Product Overview
8.6.3.1.2. Current Status of Development
8.6.3.1.3. Clinical Trials
8.6.3.1.4. Key Clinical Trial Results
 
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.2.1. PDE Inhibitors: Prominent Researchers
9.2.2. PDE Inhibitors: Leading Key Opinion Leaders
 
10. MARKET OPPORTUNITY
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Research Methodology
10.4. Overall PDE Inhibitors Market, 2016-2026
10.4.1. Overall PDE Inhibitors Market: Distribution by Therapeutic Area
10.4.2. Overall PDE Inhibitors Market: Distribution by PDE Subtype
 
10.5. Daliresp (AstraZeneca)
10.5.1. Target Patient Population
10.5.2. Sales Forecast
 
10.6. OTEZLA (Celgene)
10.6.1. Target Patient Population
10.6.2. Sales Forecast
 
10.7. Crisaborole (Anacor Pharmaceuticals)
10.7.1. Target Patient Population
10.7.2. Sales Forecast
 
10.8. OPA-15406 / MM36 (Otsuka Pharmaceutical / Medimetriks Pharmaceuticals)
10.8.1. Target Patient Population
10.8.2. Sales Forecast
 
10.9. HT-0712 (Dart NeuroScience)
10.9.1. Target Patient Population
10.9.2. Sales Forecast
 
10.10. RPL554 (Verona Pharma)
10.10.1. Target Patient Population
10.10.2. Sales Forecast
 
10.11. BI409306 (Boehringer Ingelheim)
10.11.1. Target Patient Population
10.11.2. Sales Forecast
 
10.12. NS-0200 (NuSirt Biopharma)
10.12.1. Target Patient Population
10.12.2. Sales Forecast
 
10.13. RVT-501 (Roivant Sciences)
10.13.1. Target Patient Population
10.13.2. Sales Forecast
 
10.14. CHF6001 (Chiesi Farmaceutici)
10.14.1. Target Patient Population
10.14.2. Sales Forecast
 
10.15. PF-02545920 (Pfizer)
10.15.1. Target Patient Population
10.15.2. Sales Forecast
 
10.16. TAK-063 (Takeda Pharmaceutical)
10.16.1. Target Patient Population
10.16.2. Sales Forecast
 
10.17. OMS824 (Omeros Corporation)
10.17.1. Target Patient Population
10.17.2. Sales Forecast
 
11. DISCONTINUED MOLECULES AND SIDE EFFECTS
11.1. Chapter Overview
11.2. Discontinued Molecules
11.2.1. Discontinued / Terminated Molecules: Distribution by Phase of Development
11.2.2. Discontinued / Terminated Molecules: Distribution by PDE Subtype
11.3. Precautionary Notes and Common Side Effects
11.3.1. PDE5 Inhibitors
11.3.2. PDE4 Inhibitors
 
12 CONCLUSION
12.1. The Pipeline Is Dominated By the Presence of PDE4, PDE5 and PDE10 Inhibitors
12.2. Both Big and Small Pharma Players, Keen to Leverage the Broad Spectrum Applicability of This Drug Class, are Actively Involved
12.3. Involvement of Several Prominent Researchers in This Domain and Growing Social Media Chatter Are Indicative of the Popularity of This Drug Class
12.4. Varying Opportunity across Disease Indications is Likely to Translate into a Lucrative Future Growth Potential
 
13. INTERVIEW TRANSCRIPTS
 
14. APPENDIX: TABULATED DATA
15. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS

List of Figures

Figure 3.1  Schematic Representation of Phosphodiesterases
Figure 3.2  PDE Isozymes: Function
Figure 4.1  PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Figure 4.2  PDE Inhibitors: Distribution by PDE Subtypes
Figure 4.3  PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Figure 4.4  PDE Inhibitors: Distribution by Therapeutic Areas
Figure 4.5  PDE Inhibitors: Distribution by Key Therapeutic Indications
Figure 4.6  PDE Inhibitors: Distribution by PDE Subtype, Therapeutic Area and Phase of Development
Figure 4.7  PDE Inhibitors: Distribution by Route of Administration
Figure 4.8  PDE Inhibitors: Distribution by Geography
Figure 4.9  PDE Inhibitors: Regional Landscape
Figure 4.10 PDE Inhibitors: Leading Players
Figure 5.1  Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Figure 5.2  PDE Inhibitors: Most Popular Marketed Drugs on Twitter, 2010-2015
Figure 5.3  PDE Inhibitors: Most Popular PDE Inhibitor Subtypes on Twitter, 2010-2015
Figure 5.4  PDE Inhibitors: Most Popular Keywords on Twitter, 2010-2015
Figure 6.1  Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Figure 6.2  Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Figure 6.3  Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Figure 6.4  Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 6.5  Pfizer: Annual Revenues, 2011 – H1 2016 (USD Billion)
Figure 6.6  Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Figure 6.7  Omeros Corporation: Annual Revenues, 2011- H1 2016 (USD Million)
Figure 6.8  Omeros Corporation: Funding Instances (USD Million)
Figure 7.1  Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Figure 7.2  Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Figure 7.3  Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Figure 8.1  Chiesi Farmaceutici: Annual Revenues, 2010-2015 (EUR Billion)
Figure 8.2  Verona Pharma: Funding Instances (GBP Million)
Figure 8.3  NuSirt Biopharma: Funding Instances (USD Million)
Figure 9.1  PDE Inhibitors: Mapping Prominent Researchers
Figure 9.2  PDE Inhibitors: Leading Key Opinion Leaders
Figure 10.1  Overall PDE Inhibitors Market, 2016-2026, Base Scenario (USD Million)
Figure 10.2  Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Figure 10.3 Evolution of PDE Inhibitors Market: Distribution by Therapeutic Area 2016, 2021, 2026 (Base Scenario)
Figure 10.4 Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Figure 10.5  Evolution of PDE Inhibitors Market: Distribution by PDE Subtype 2016, 2021, 2026 (Base Scenario)
Figure 10.6  Daliresp Sales Forecast, Base Scenario (USD Million)
Figure 10.7  OTEZLA Sales Forecast, Base Scenario (USD Million)
Figure 10.8  Crisaborole Sales Forecast, Base Scenario (USD Million)
Figure 10.9  OPA-15406 Sales Forecast, Base Scenario (USD Million)
Figure 10.10 HT-0712 Sales Forecast, Base Scenario (USD Million)
Figure 10.11 RPL554 Sales Forecast, Base Scenario (USD Million)
Figure 10.12 BI409306 Sales Forecast, Base Scenario (USD Million)
Figure 10.13 NS-0200 Sales Forecast, Base Scenario (USD Million)
Figure 10.14 RVT-501 Sales Forecast, Base Scenario (USD Million)
Figure 10.15 CHF6001 Sales Forecast, Base Scenario (USD Million)
Figure 10.16 PF-02545920 Sales Forecast, Base Scenario (USD Million)
Figure 10.17 TAK-063 Sales Forecast, Base Scenario (USD Million)
Figure 10.18 OMS824 Sales Forecast, Base Scenario (USD Million)
Figure 11.1 Discontinued / Terminated Molecules: Distribution by Phase of Termination
Figure 11.2 Discontinued / Terminated Molecules: Distribution by PDE Subtype
Figure 12.1 PDE Inhibitors: Developer Landscape
Figure 12.2 PDE Inhibitors: Key Indications
Figure 12.3 PDE Inhibitors: Market Opportunity across Different Disease Indications
Figure 12.4 PDE Inhibitors Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2026 (USD Billion)

List of Tables

Table 3.1  PDE Superfamily
Table 3.2  Non-selective PDE Inhibitors
Table 4.1  PDE Inhibitors: Marketed and Developmental Pipeline 
Table 4.2  PDE Inhibitors: Unknown Status
Table 5.1  PDE Inhibitors: Genitourinary and Cardiovascular Diseases
Table 5.2  Hanmi Pharmaceuticals: PDE Inhibitor Pipeline
Table 5.3  HGP1207: Current Status of Development
Table 5.4  HGP1207: Clinical Trials
Table 5.5  HCP1303: Current Status of Development
Table 5.6  HCP1303: Clinical Trials
Table 6.1  PDE Inhibitors Pipeline: Neurological Diseases
Table 6.2  Boehringer Ingelheim: PDE Inhibitor Pipeline
Table 6.3  BI 409306: Current Status of Development
Table 6.4  BI 409306: Clinical Trials
Table 6.5  BI 409306: Clinical Trial Results (NCT01505894)
Table 6.6  BI 409306: Clinical Trial Results (NCT01611311)
Table 6.7  Takeda Pharmaceuticals: PDE Inhibitor Pipeline
Table 6.8  TAK-063: Current Status of Development
Table 6.9  TAK-063: Clinical Trials
Table 6.10  Pfizer: PDE Inhibitor Pipeline
Table 6.11  PF-02545920: Current Status of Development
Table 6.12  PF-02545920: Clinical Trials
Table 6.13  Dart NeuroScience: PDE Inhibitor Pipeline
Table 6.14  HT-0712: Current Status of Development
Table 6.15  HT-0712: Clinical Trials
Table 6.16  Omeros Corporation: PDE Inhibitor Pipeline
Table 6.17  OMS824: Current Status of Development
Table 6.18  OMS824: Clinical Trials
Table 7.1  PDE Inhibitors Pipeline: Dermatological Disorders
Table 7.2  Anacor Pharmaceuticals: PDE Inhibitors Pipeline
Table 7.3  Crisaborole: Current Status of Development
Table 7.4  Crisaborole: Clinical Trials
Table 7.5  Crisaborole: Phase III Clinical Trial Results
Table 7.6  Otsuka: PDE Inhibitor Pipeline
Table 7.7  OPA-15406: Current Status of Development
Table 7.8  OPA-15406: Clinical Trials
Table 7.9  Roivant Sciences: PDE Inhibitor Pipeline
Table 7.10  RVT-501: Current Status of Development
Table 7.11  RVT-501: Clinical Trials
Table 8.1  PDE Inhibitors Pipeline: Respiratory Diseases
Table 8.2  PDE Inhibitors: Marketed and Pipeline (Other Indications)
Table 8.3  Chiesi Farmaceutici: PDE Inhibitor Pipeline
Table 8.4  CHF6001: Current Status of Development
Table 8.5  CHF6001: Clinical Trials
Table 8.6  Verona Pharma: PDE Inhibitor Pipeline
Table 8.7  RLP554: Current Status of Development
Table 8.8  RLP554: Clinical Trials
Table 8.9  NuSirt: PDE Inhibitor Pipeline
Table 8.10  NS-0200: Current Status of Development
Table 8.11  NS-0200: Clinical Trials
Table 9.1  KOLs: Phase IV Clinical Trials
Table 9.2  KOLs: Phase III Clinical Trials
Table 9.3  KOLs: Phase II Clinical Trials
Table 9.4  KOLs: Phase I Clinical Trials
Table 9.5  KOLs: Other Clinical Trials
Table 10.1  Marketed / Late Phase PDE Inhibitors: Actual / Estimated Launch Year
Table 10.2  Daliresp: Target Patient Population
Table 10.3  OTEZLA: Target Patient Population
Table 10.4  Crisaborole: Target Patient Population
Table 10.5  OPA-15406: Target Patient Population
Table 10.6  HT-0712: Target Patient Population
Table 10.7  RPL554: Target Patient Population
Table 10.8  BI409306: Target Patient Population
Table 10.9  NS-0200: Target Patient Population
Table 10.10  RVT-501: Target Patient Population
Table 10.11  CHF6001: Target Patient Population
Table 10.12  PF-02545920: Target Patient Population
Table 10.13  TAK-063: Target Patient Population
Table 10.14  OMS824: Target Patient Population
Table 11.1  PDE Inhibitors: Discontinued / Terminated Molecules,
Table 14.1  PDE Inhibitors: Distribution by Phase of Development (Marketed/ Phase III / Phase II / Phase I / Preclinical / Discovery)
Table 14.2  PDE Inhibitors: Distribution by PDE Subtypes
Table 14.3  PDE Inhibitors: Distribution by PDE Subtypes and Phase of Development
Table 14.4  PDE Inhibitors: Distribution by Therapeutic Areas
Table 14.5  PDE Inhibitors: Distribution by Key Therapeutic Indications
Table 14.6  PDE Inhibitors: Distribution by Route of Administration
Table 14.7  PDE Inhibitors: Distribution by Geography
Table 14.8  PDE Inhibitors: Leading Players
Table 14.9  Hanmi Science Holding: Annual Revenues, 2011 - H1 2016 (KRW Billion)
Table 14.10 Boehringer Ingelheim: Annual Revenues, 2010-2015 (EUR Billion)
Table 14.11  Boehringer Ingelheim: Revenues Distribution by Business Segments, 2015 (EUR Billion)
Table 14.12  Takeda Pharmaceuticals: Annual Revenues, 2010-Q1 2016 (JPY Billion)
Table 14.13  Takeda Pharmaceuticals: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.14  Pfizer: Annual Revenues, 2011 – Q1 2016 (USD Billion)
Table 14.15  Pfizer: Revenue Distribution by Business Segments, 2015 (USD Billion)
Table 14.16  Omeros Corporation: Annual Revenue, 2011- H1 2016 (USD Million)
Table 14.17  Omeros Corporation: Funding Instances (USD Million)
Table 14.18  Anacor Pharmaceuticals: Annual Revenues, 2011 – Q1 2016 (USD Million)
Table 14.19  Otsuka: Annual Revenues, 2011-H1 2016 (JPY Billion)
Table 14.20  Otsuka: Revenue Distribution by Business Segments, 2015 (JPY Billion)
Table 14.21  Chiesi Farmaceutici: Annual Revenue, 2010-2015 (EUR Billion)
Table 14.22  Verona Pharma: Funding Instances (GBP Million)
Table 14.23  NuSirt Biopharma: Funding Instances (USD Million)
Table 14.24  Overall PDE Inhibitors Market, 2016-2026, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.25  Overall PDE Inhibitors Market: Distribution by Therapeutic Area, 2016-2026 (USD Million)
Table 14.26  Overall PDE Inhibitors Market: Distribution by PDE Subtype, 2016-2026 (USD Million)
Table 14.27  Daliresp Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.28  OTEZLA Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.29  Crisaborole Sales Forecast, Base Scenario (USD Million)
Table 14.30  OPA-15406 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.31  HT-0712 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.32  RPL554 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.33  BI409306 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.34  NS-0200 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.35  RVT-501 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.36  CHF6001 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.37  PF-02545920 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.38  TAK-063 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.39  OMS824 Sales Forecast, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.40  Discontinued / Terminated Molecules: Distribution by Phase of Termination
Table 14.41  Discontinued / Terminated Molecules: Distribution by PDE Subtype

Listed Companies

The following companies and organizations have been mentioned in the study.

  1. Auxilium Pharmaceuticals
  2. Aalborg University
  3. Academisch Medisch Centrum
  4. Actavis
  5. AIDS Malignancy Consortium
  6. Ajou University Hospital
  7. Albany Medical Center
  8. Alfred Hospital
  9. Alhayah national hospital
  10. All India Institute of Medical Sciences
  11. Amgen
  12. Anacor Pharmaceuticals
  13. Anzhen hospital
  14. APHP - Hôpital Raymond-Poincaré
  15. Aravis Venture
  16. ARCH Ventures
  17. Army R&R Hospital
  18. Asan Medical Center
  19. Assiut University
  20. Astellas Pharma
  21. AstraZeneca
  22. Atlanta Gastroenterology Associates
  23. Aventis
  24. Baxter Healthcare Corp
  25. Bayer
  26. Baylor Research Institute
  27. Beijing University First Hospital
  28. BioCrea
  29. Boehringer Ingelheim
  30. Boston University School of Medicine
  31. Bucheon St.Mary's Hospital
  32. Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
  33. Carinopharm
  34. Carlos Haya Hospital Complex
  35. Carolinas Healthcare System
  36. Catalina Research Institute
  37. Catholic University Medical College
  38. Cedars-Sinai Medical Center
  39. Celerion
  40. Celgene
  41. Centre for Human Drug Research (the Netherlands)
  42. Centre Hospitalier Régional Universitaire de Lille
  43. Centre Hospitalier Universitaire de Sherbrooke
  44. Chiesi Farmaceutici
  45. Children's Healthcare of Atlanta at Egleston
  46. Children's Hospital Colorado
  47. Children's Hospital of Philadelphia
  48. China Medical University Hospital
  49. Chonbuk National University Hospital
  50. Chong Kun Dang Pharmaceutical
  51. Chonnam National University Hospital
  52. CHRU de Nîmes - Hôpital Universitaire Carémeau
  53. Chulalongkorn University
  54. Chungang University Hospital
  55. Chungbuk National University Hospital
  56. Chungnam National University Hospital
  57. CIM Sant Pau - IIB Sant Pau
  58. Cincinnati Children’s Hospital Medical Center
  59. Clinical Pharmacology of Miami
  60. Clinique Beau Soleil
  61. Columbia University
  62. Comprehensive Cancer Center of Wake Forest University
  63. Concert Pharmaceuticals
  64. Cristalia
  65. CTC Bio
  66. Daiichi Sankyo
  67. Danish Cancer Society Research Center
  68. Danish Headache Center
  69. Dart NeuroScience
  70. Dong-A Pharmaceutical
  71. Dongkook Pharmaceuticals
  72. Duke University
  73. Eisai
  74. elbion
  75. Eli Lilly
  76. Ewha Womans University Mokdong Hospital
  77. FORUM Pharmaceuticals (EnVivo Pharmaceuticals)
  78. Freeman Hospital
  79. Frontage Clinical Services
  80. Fundación Jiménez Díaz
  81. Fuwai Hospital
  82. Gachon University
  83. Georgia Regents University
  84. GI Specialists of Georgia
  85. Govind Ballabh Pant Hospital
  86. GSK
  87. Gulf Coast Heart Clinic
  88. Hallym University Medical Center
  89. Hamad Medical Corporation
  90. Hammersmith Medicines Research
  91. Hanmi Pharmaceutical
  92. HAR de Loja
  93. Hatteras Venture Partners
  94. Heart Center of Chonnam National University Hospital
  95. Helicon Therapeutics
  96. Helse Stavanger HF
  97. Hoffmann-La Roche
  98. Hospira
  99. Hospital Ana Nery - Federal University of Bahia
  100. Hospital Clinic of Barcelona
  101. Hospital Clínico Universitario San Carlos
  102. Hospital de Jerez
  103. Hospital for State Civil Servants of Sao Paulo
  104. Hospital General Universitario Gregorio Marañón
  105. Hospital Universitario Doce de Octubre
  106. Hospital Universitario La Paz
  107. Hospital Universitario La Princesa
  108. Hospital Universitario Pedro Ernesto
  109. Hospital Universitario Ramón y Cajal
  110. Hospital Universitario Reina Sofía
  111. Hospital Universitario Virgen Macarena
  112. Icahn School of Medicine at Mount Sinai
  113. ICM Brain and Spine Insitute
  114. Imperial College London
  115. Indiana University
  116. Inflazyme Pharmaceuticals
  117. Inha University Hospital
  118. Inje University
  119. Innovaderm Research
  120. Instituto do Coração (InCor)
  121. Intra-Cellular Therapies
  122. Ipiranga Hospital
  123. Iranian's Ministry of health
  124. Jasper Clinic
  125. Johns Hopkins University
  126. JW Pharmaceuticals
  127. Kangdong Sacred Heart Hospital
  128. Kerckhoff Heart Center
  129. King’s College London
  130. Kings County Hospital Center
  131. Kobe City Medical Center General Hospital
  132. Konkuk University Medical Center
  133. Konyang University Hospital
  134. Korea University Anam Hospital
  135. Korea University Guro Hospital
  136. Kosair Pediatric Research Unit
  137. Kowa Company
  138. Kyorin Pharmaceuticals
  139. Kyung Hee University
  140. Laval University
  141. Le Bonheur Children’s Medical Center
  142. Leiden University Medical Center
  143. Maastricht University
  144. Maimonides Medical Center
  145. Mansoura University
  146. Maruho
  147. Massachusetts General Hospital
  148. Mayo Clinic
  149. McGill University
  150. McGuire VAMC
  151. MDS Pharma Services
  152. Meda Pharma
  153. Medical University of South Carolina
  154. Medical University of Vienna
  155. Medicines Evaluation Unit
  156. Medicinova
  157. Medimetriks Pharmaceuticals
  158. Menarini
  159. Menoufia University
  160. Merck
  161. Mezzion Pharma
  162. Mironid
  163. Mitsubishi Tanabe Pharma
  164. Montreal Heart Institute
  165. Mountain Group Partners
  166. Nanjing First Hospital, Nanjing Medical University
  167. National Cerebral and Cardiovascular Center
  168. National Cheng-Kung University Hospital
  169. National Heart, Lung, and Blood Institute (NHLBI)
  170. National Institute of Allergy and Infectious Diseases (NIAID)
  171. National Institute of Cardiology, Ministry of Health, Brazil
  172. National Institute of Neurological Disorders and Stroke (NINDS)
  173. National Institute on Aging (NIA)
  174. National Jewish Health
  175. Nationwide Children's Hospital
  176. New York State Psychiatric Institute
  177. Northwestern University
  178. Nottingham University Hospitals NHS Trust
  179. Novartis Venture Funds
  180. Nura
  181. NuSirt Biopharma
  182. Nycomed
  183. Omeros Corporation
  184. Orexo
  185. Otsuka Pharmaceutical
  186. Otto Wagner Hospital
  187. Palobiofarma
  188. PAREXEL International
  189. Perinataal Centrum MMC Veldhoven
  190. Pfizer
  191. Pharmacology Unit - University Hospital of Grenoble
  192. Plexera Therapeutics
  193. Polytechnic University of Madrid
  194. Postgraduate Institute of  Medical Education and Research
  195. Premier Clinical Research
  196. Primary Children’s Medical Center
  197. Providence Health & Services
  198. Pusan National University Hospital
  199. Quality Medical Research
  200. Queen Silvia Children´s Hospital
  201. Rabin Medical Center, Belinson Hospital
  202. Rambam Health Care Campus
  203. Respiratory Clinical Trials
  204. Rhinopharma
  205. Rigshospitalet
  206. Riley Hospital
  207. Rocky Mountain Research
  208. Roivant Sciences
  209. Royal Adelaide Hospital
  210. Sagene Pharmaceuticals
  211. Samsung Medical Center
  212. San Diego Sexual Medicine
  213. San Giovanni Battista, Hospital University of Turin
  214. Sandoz
  215. Sanjay Gandhi Postgraduate Institute of Medical Sciences
  216. Sanofi
  217. Sapienza University of Rome
  218. Seoul National University Bundang Hospital
  219. Seoul National University College of Medicine
  220. Seoul National University Hospital
  221. Seoul St. Mary's Hospital
  222. Seoul Veterans Hospital
  223. Severance Hospital
  224. Shahid Sadoughi University of Medical Science
  225. Shenyang Northern Hospital
  226. SK Chemicals
  227. Skane University Hospital
  228. SMG-SNU Boramae Medical Center
  229. Soon Chun Hyang University
  230. Soonchunhyang University Bucheon Hospital
  231. Specialties Hospital Complex Juan Ramon Jimenez
  232. St George's, University of London
  233. Stanford University Medical Center
  234. Stanley Medical Research Institute
  235. State University of Rio de Janeiro
  236. Sterling Research
  237. Symyoo
  238. Taiho Pharmaceutical
  239. Takeda Pharmaceuticals
  240. Tameside Hospital NHS Foundation Trust
  241. Tehran University of Medical Sciences
  242. Temple University Hospital
  243. Tetra Discovery partners
  244. Teva Pharmaceutical
  245. The Catholic University of Korea
  246. The Cleveland Clinic
  247. The First Affiliated Hospital of Nanjing Medical University
  248. The Hospital for Sick Children
  249. The Kennedy Krieger Institute
  250. The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
  251. The University of Texas Health Science Center at San Antonio
  252. Transitional Learning Center, University of Texas
  253. TriStar Technology Ventures
  254. Tritechbiopharm
  255. Tulane Medical Center
  256. Uniformed Services University of the Health Sciences
  257. United Therapeutics
  258. University College London
  259. University Health Network
  260. University Hospital Centre (CHU) de Lyon
  261. University Hospital Erlangen
  262. University Hospital in Angers
  263. University Hospital of Antwerp
  264. University Hospital of Puerto Real
  265. University Hospital, Angers
  266. University Hospitals Leuven
  267. University Hospitals Seidman Cancer Center
  268. University Magna Graecia of Catanzaro
  269. University Medical Center Groningen
  270. University Medical Centre Ljubljana
  271. University of Adelaide
  272. University of Alabama at Birmingham
  273. University of Arizona
  274. University of British Columbia
  275. University of California
  276. University of Campinas
  277. University of Cincinnati
  278. University of Cologne
  279. University of Connecticut Health Center
  280. University of Copenhagen Herlev Hospital
  281. University of Dundee
  282. University Of Edinburgh
  283. University of Florence
  284. University of Gothenburg
  285. University of Guadalajara
  286. University of Iowa
  287. University of Kentucky
  288. University of Leicester
  289. University of Manitoba
  290. University of Miami
  291. University of Nebraska
  292. University of North Carolina
  293. University of Nottingham
  294. University of Roma La Sapienza
  295. University of Santo Tomas Hospital
  296. University of South Florida
  297. University of Texas
  298. University of Tor Vergata
  299. University of Ulsan, Asan Medical Center
  300. University of Utah
  301. University of Western Ontario
  302. Vall Hebron Hospital
  303. Vanderbilt University
  304. Verona Pharma
  305. Viking Global Investors
  306. Virginia Commonwealth University
  307. Vita-Salute San Raffaele Hospital
  308. VIVUS
  309. vtv Therapeutics
  310. VU Medisch Centrum
  311. Wake Forest Baptist Health
  312. Warner Chilcott
  313. Washington University School of Medicine
  314. Wonju College of Medicine
  315. Xijing Hospital
  316. Yangji Hospital
  317. Yangsan Busan University Hospital
  318. Yeungnam University
  319. Yonsei University
  320. Yuebei People's Hospital
  321. Zalicus
  322. ZNA Middelheim
  323. Zydus Cadila

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com